<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102655">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02088060</url>
  </required_header>
  <id_info>
    <org_study_id>CBD-FEP</org_study_id>
    <secondary_id>2012-004335-23</secondary_id>
    <nct_id>NCT02088060</nct_id>
  </id_info>
  <brief_title>A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol as a Treatment for Acutely Ill Schizophrenic Patients</brief_title>
  <official_title>A Four-week, Multicentre, Double-blinded, Randomised, Active- and Placebo- Controlled, Parallel-group Trial Investigating Efficacy and Safety of Cannabidiol in Acute, Early-stage Schizophrenic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Institute of Mental Health, Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Martin-Luther-Universität Halle-Wittenberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tangent Data Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Glostrup University Hospital, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Institute of Mental Health, Mannheim</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <authority>Romania: National Medicines Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Schizophrenia is a heterogeneous mental disorder that affects one percent of the world's
      population. Current antipsychotics are only partially effective, and their use is often
      associated with serious side effects. Cannabidiol is a natural counterpart of the
      psychoactive component of marijuana, delta-9-tetrahydrocannabinol. While cannabidiol  has no
      psychotomimetic or addictive properties, it indirectly affects endogenous cannabinoid
      signalling by impairing the degradation of the endocannabinoid anandamide. In a controlled
      clinical trial of cannabidiol versus amisulpride (an established antipsychotic) in acute
      paranoid schizophrenics the investigators showed a significant clinical improvement in all
      symptoms of schizophrenia compared to baseline with either treatment. But cannabidiol
      displayed a significantly superior side-effect profile. This study is to evaluate the
      efficacy and safety of this novel treatment option in comparison to placebo and olanzapine,
      an established second generation antipsychotic in the treatment of acute schizophrenia and
      schizophrenia maintenance therapy, in a four-week clinical trial.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in the Positive and Negative Syndrome Scale (PANSS) total score</measure>
    <time_frame>within 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes  in the PANSS subscores and clusters</measure>
    <time_frame>within 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Clinical Global Impression score</measure>
    <time_frame>within 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Global Assessment of Functioning Scale</measure>
    <time_frame>within 4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Personal and Social Performance Scale</measure>
    <time_frame>within 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Calgary Depression Scale for Schizophrenia</measure>
    <time_frame>within 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Hamilton Anxiety Scale</measure>
    <time_frame>within 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cognitive skills</measure>
    <time_frame>within 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to antipsychotic medication</measure>
    <time_frame>within 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of endogenous cannabinoids</measure>
    <time_frame>within 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in physiological parameter</measure>
    <time_frame>within 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the UKU Side Effect Rating Scale</measure>
    <time_frame>within 4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Columbia Suicidality Severity Rating Scale</measure>
    <time_frame>within 4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Cannabidiol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cannabidiol tablets 300 mg twice a day and placebo olanzapine capsule once a day over 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Olanzapine capsule 15mg once a day and placebo cannabidiol tablets twice a day over 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo cannabidiol tablets twice a day and placebo olanzapine capsule once a day over 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol</intervention_name>
    <description>Cannabidiol tablets</description>
    <arm_group_label>Cannabidiol</arm_group_label>
    <other_name>Arvisol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Olanzapine capsules</description>
    <arm_group_label>Olanzapine</arm_group_label>
    <other_name>Olanzapine 1A pharma</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Cannabidiol</intervention_name>
    <description>Placebo cannabidiol tablets</description>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Olanzapine</intervention_name>
    <description>Placebo olanzapine capsule</description>
    <arm_group_label>Cannabidiol</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent given by the subject

          -  DSM-IV-TR diagnosis of schizophrenic psychosis (295.10, 295.20, 295.30, 295.90
             (American Psychiatric Association)

          -  Patients must be within the first three years of illness, i.e. first diagnosis of
             schizophrenia is no older than three years.

          -  Age 18 to 65 years, male or female

          -  Minimal initial PANSS score of 75 at baseline

          -  Female patients of childbearing potential need to utilize a proper method of
             contraception.

          -  Body Mass Index between 18 and 40

        Exclusion Criteria:

          -  Lack of accountability (assessed by an independent psychiatrist)

          -  History of treatment-resistant schizophrenia, defined as no response to at least two
             antipsychotics given for a minimum of 6 weeks each in an adequate dosage

          -  Positive urine drug-screening for illicit drugs at screening (except cannabinoids and
             benzodiazepines)

          -  Serious suicidal risk at screening visit (Subject to investigator's and independent
             psychiatrist's judgement: Poses a serious suicidal or homicidal risk at screening
             visit or has made a serious suicide attempt within the last 12 months prior to
             screening visit, or has exhibited homicidal behaviour at anytime during her/his
             lifetime)

          -  Known intolerance or allergy to olanzapine or cannabidiol

          -  Other relevant interferences of axis 1 (e.g. serious depression) according to
             diagnostic evaluation (MINI) including residual forms of schizophrenia

          -  Pregnancy, as determined through a β-HCG pregnancy test, or lactation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>F. Markus Leweke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Institute of Mental Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>F. Markus Leweke, MD</last_name>
    <phone>+49 621 1703 2321</phone>
    <email>leweke@cimh.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cathrin Rohleder, PhD</last_name>
    <phone>+49 621 1703 2333</phone>
    <email>rohleder@cimh.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Psychiatric Centre Glostrup</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of General Psychiatry, Heidelberg University</name>
      <address>
        <city>Heidelberg</city>
        <state>BW</state>
        <zip>68115</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dagmar Koethe, MD</last_name>
      <email>Dagmar.Koethe@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Dagmar Koethe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dep. of Psychiatry and Psychotherapy, Central Institute of Mental Health</name>
      <address>
        <city>Mannheim</city>
        <state>BW</state>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>F. Markus Leweke, MD</last_name>
      <phone>+49 621 1703</phone>
      <phone_ext>2321</phone_ext>
      <email>leweke@cimh.de</email>
    </contact>
    <contact_backup>
      <last_name>Cathrin Rohleder, PhD</last_name>
      <phone>+49 621 1703</phone>
      <phone_ext>2333</phone_ext>
      <email>rohleder@cimh.de</email>
    </contact_backup>
    <investigator>
      <last_name>J. Malte Bumb, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juliane K. Mueller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>F. Markus Leweke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Psychiatry and Psychotherapy, Technical University Munich</name>
      <address>
        <city>Munich</city>
        <state>BY</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Psychiatry and Psychotherapy, Ludwig-Maximillians-University Munich</name>
      <address>
        <city>Munich</city>
        <state>BY</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Psychiatry and Psychotherapy, Martin-Luther-University, Halle/Wittenberg</name>
      <address>
        <city>Halle</city>
        <state>ST</state>
        <zip>06112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 13, 2014</lastchanged_date>
  <firstreceived_date>March 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
